Literature DB >> 16267742

Transient viremia in HIV-infected patients and use of plasma preparation tubes.

Valentina Stosor1, Frank J Palella, Baiba Berzins, Michele Till, Angel Leake, Joan S Chmiel, Robert L Murphy.   

Abstract

Using plasma preparation tubes for the collection and storage of plasma resulted in factitious, low-level human immunodeficiency virus type 1 (HIV-1) viremia among patients receiving highly active antiretroviral therapy who incurred unnecessary additional clinic visits, laboratory testing, and medication changes. We caution clinicians against the routine use of plasma preparation tubes for collection of blood samples for HIV-1 level 1 quantification.

Entities:  

Mesh：

Year:  2005        PMID： 16267742     DOI： 10.1086/498025

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  21 in total

1.  Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.

Authors:  Thomas P Young; Gavin Cloherty; Signe Fransen; Laura Napolitano; Priscilla Swanson; Christine Herman; Neil T Parkin; John Hackett
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

2.  Evaluation of effect of specimen-handling parameters for plasma preparation tubes on viral load measurements obtained by using the Abbott RealTime HIV-1 load assay.

Authors:  Helen Fernandes; Svetlana Morosyuk; Klara Abravaya; Madhuri Ramanathan; Lynne Rainen
Journal:  J Clin Microbiol       Date:  2010-05-19       Impact factor: 5.948

3.  Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.

Authors:  J Troy Grennan; Mona R Loutfy; DeSheng Su; P Richard Harrigan; Curtis Cooper; Marina Klein; Nima Machouf; Julio S G Montaner; Sean Rourke; Christos Tsoukas; Bob Hogg; Janet Raboud
Journal:  J Infect Dis       Date:  2012-04-15       Impact factor: 5.226

4.  Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA.

Authors:  H Wan; A Seth; L Rainen; H Fernandes
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

5.  Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.

Authors:  Julia Fleming; W Christopher Mathews; Richard M Rutstein; Judith Aberg; Charurut Somboonwit; Laura W Cheever; Stephen A Berry; Kelly A Gebo; Richard D Moore
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

6.  Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 test.

Authors:  Colleen S Kraft; José Nilo G Binongo; Eileen M Burd; Molly E Eaton; Cindy B McCloskey; Helen Fernandes; Charles E Hill; Angela M Caliendo
Journal:  J Clin Virol       Date:  2013-01-16       Impact factor: 3.168

7.  Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes.

Authors:  Anne-Marte Bakken Kran; Tom Øystein Jonassen; Mette Sannes; Kirsti Jakobsen; Andreas Lind; Arild Maeland; Mona Holberg-Petersen
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

8.  CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.

Authors:  Babafemi Taiwo; Peter W Hunt; Rajesh T Gandhi; Andrew Ellingson; Matthew McKenna; Jeffrey M Jacobson; Barbara Gripshover; Ronald J Bosch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

9.  Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures.

Authors:  Peter F Rebeiro; Asghar Kheshti; Sally S Bebawy; Samuel E Stinnette; Husamettin Erdem; Yi-Wei Tang; Timothy R Sterling; Stephen P Raffanti; Richard T D'Aquila
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

10.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.